"WINDOW" FOR FDA REFORM DEBATE ON SENATE FLOOR SOUGHT BY MAJORITY LEADER LOTT; LABOR COMMITTEE REPORT ON S 1477 RELEASED WITHOUT BUDGET SCORING
This article was originally published in The Gray Sheet
Executive Summary
Senate Majority Leader Trent Lott (R-Miss.) says he is "looking for a window to take up" FDA reform legislation following Congress' Fourth of July recess.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.